• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerveau inks licensing deal with AbbVie for tau imaging agent

October 23, 2017 By Sarah Faulkner

Cerveau TechnologiesCerveau Technologies has inked a deal to license and supply AbbVie (NYSE:ABBV) with its [F-18]MK-6240 investigational tau imaging agent, the company said today.

After the FDA cleared the investigational new drug application for Cerveau’s imaging agent in June, the company said it planned to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain.

NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like Alzheimer’s disease. Cerveau’s partnership with AbbVie is slated to focus on the use of [F-18]MK-6240 as a biomarker in clinical trials of drugs being developed for the treatment of Alzheimer’s disease.

“At Cerveau we are focused on enhancing access to key technologies that we believe have the potential to advance human health” CEO Rick Hiatt said in prepared remarks. “We are excited by the opportunity to work with AbbVie with the goal of expanding the availability of this novel investigational imaging agent to the broader scientific community.”

Cerveau holds a global license for the imaging agent from Merck (NYSE:MRK).

Filed Under: Clinical Trials, Featured, Imaging, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Cerveau Technologies

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS